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ABSTRACT A novel avian-origin H7N9 influenza A virus (IAV) emerged in China in 2013, causing mild to lethal human respira-
tory infections. H7N9 originated with multiple reassortment events between avian viruses and carries genetic markers of human
adaptation. Determining whether H7N9 induces a host response closer to that with human or avian IAV is important in order to
better characterize this emerging virus. Here we compared the human lung epithelial cell response to infection with A/Anhui/
01/13 (H7N9) or highly pathogenic avian-origin H5N1, H7N7, or human seasonal H3N2 IAV. The transcriptomic response to
H7N9 was highly specific to this strain but was more similar to the response to human H3N2 than to that to other avian IAVs.
H7N9 and H3N2 both elicited responses related to eicosanoid signaling and chromatin modification, whereas H7N9 specifically
induced genes regulating the cell cycle and transcription. Among avian IAVs, the response to H7N9 was closest to that elicited by
H5N1 virus. Host responses common to H7N9 and the other avian viruses included the lack of induction of the antigen presenta-
tion pathway and reduced proinflammatory cytokine induction compared to that with H3N2. Repression of these responses
could have an important impact on the immunogenicity and virulence of H7N9 in humans. Finally, using a genome-based drug
repurposing approach, we identified several drugs predicted to regulate the host response to H7N9 that may act as potential anti-
virals, including several kinase inhibitors, as well as FDA-approved drugs, such as troglitazone and minocycline. Importantly, we
validated that minocycline inhibited H7N9 replication in vitro, suggesting that our computational approach holds promise for
identifying novel antivirals.
IMPORTANCE Whether H7N9 will be the next pandemic influenza virus or will persist and sporadically infect humans from its
avian reservoir, similar to H5N1, is not known yet. High-throughput profiling of the host response to infection allows rapid
characterization of virus-host interactions and generates many hypotheses that will accelerate understanding and responsive-
ness to this potential threat. We show that the cellular response to H7N9 virus is closer to that induced by H3N2 than to that in-
duced by H5N1, reflecting the potential of this new virus for adaptation to humans. Importantly, dissecting the host response to
H7N9 may guide host-directed antiviral development.
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Between February and May 2013, the novel avian influenza A(H7N9) virus was associated with 132 human cases, including
37 deaths, occurring mainly in Eastern China (1). Most reports of
infection have presented a severe clinical picture characterized by
bilateral pneumonia progressing to acute respiratory distress syn-
drome associated with a cytokine storm and multiorgan failure (2,
3). This clinical presentation is similar to that with H5N1 infection
(2, 3) but is unusual for H7 viruses, which cause mostly mild
respiratory illness or conjunctivitis (4). The hospitalized case fa-
tality rate for H7N9 is estimated at 36% (5), compared to 60 to
70% for H5N1 (6, 7) and 6.5 to 8% for seasonal influenza infection
(8, 9). However, mild cases of H7N9 infections were recently de-
tected through sentinel influenza-like illness surveillance, suggest-
ing that H7N9 could have caused a substantial number of asymp-
tomatic to moderate infections (5, 10). This is in line with
infections by most influenza virus strains, with the exception of
H5N1, for which there is no report of a laboratory-confirmed mild
case of infection. Other epidemiological differences between
H7N9 and H5N1 include the more rapid accumulation of human
infections with H7N9 than with H5N1 and differences in the age
distribution of infected individuals, with H5N1 infections occur-
ring mostly in children and young adults while 55% of H7N9 cases
have been in individuals older than 60 years (7).
Sequence analysis indicates that H7N9 originated from multi-
ple reassortment events between avian influenza viruses (11, 12).
However, the H7N9 sequence bears several genetic markers of
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human adaptation, including PB2 E627K and hemagglutinin
(HA) Q226L (11, 13). The consequence of these mutations for the
host response has not been assessed. Previous studies of H7N9
virus-host interaction have focused on transmissibility and HA
binding properties. The H7N9 strain A/Anhui/01/13 (Anhui01)
has a mixed 2-3/2-6 receptor preference, associated with a ca-
pacity to efficiently transmit by direct contact but poorly by respi-
ratory droplets in the ferret model (14). These properties are in-
termediary between human seasonal influenza viruses that have
an 2-6 preference and efficiently transmit by respiratory droplets
and H5N1 viruses with an 2-3 preference that do not transmit
efficiently in either respiratory droplet or direct-contact transmis-
sion models (14, 15). Crystallographic structures of HA from
H7N9 strains isolated from human patients show that increased
avidity for human receptors compared to that of avian H7 virus is
due to the Q226L and G186V mutations (16). Assays of HA bind-
ing to human tissue sections revealed an intermediate binding
pattern between human IAV (preferentially binding nonciliated
cells of apical regions of the trachea) and H5N1 (binding alveolar
sections). In addition, a single mutation, G228S, substantially in-
creased HA binding to human receptors in the human respiratory
tract (17).
There is great concern over potential further adaptation of
H7N9 to humans and acquisition of sustainable person-to-person
transmissibility. In addition, a recent study pointed out that H7N9
acquired resistance to neuraminidase (NA) inhibitors in 2 out of
14 hospitalized patients that had been treated with oseltamivir or
peramivir (18). Emergence of H7N9 virus resistant to neuramin-
idase inhibitors is concerning, since this virus is also naturally
resistant to M2 ion channel blockers and no vaccine is yet avail-
able.
In this study, we applied global transcriptomic profiling to hu-
man cells infected with H7N9 Anhui01 or with other avian or
human IAV to broadly characterize the host response to infection
and quickly identify FDA-approved drugs that may act as antivi-
rals. We show that H7N9 induces both a specific response and
responses intermediate between those to H3N2 and those to avian
H5N1 and H7N7. Notably, H7N9 induced a downregulation of
the antigen presentation pathway and delayed proinflammatory
cytokine induction to a greater extent than H5N1 and H7N7,
which could have an important impact on in vivo immune re-
sponses. Similar to H3N2, H7N9 induced minor changes in eico-
sanoid signaling and genes implicated in chromatin modification.
Finally, we computationally predicted that several FDA-approved
drugs were able to reverse the host response to H7N9 and may be
antivirals against this emerging virus. One of these drugs, mino-
cycline, exhibited anti-H7N9 activity in vitro.
RESULTS
H7N9 replicates to levels similar to those of other avian or hu-
man IAVs in human bronchial epithelial cells. Polarized human
bronchial epithelial cells (Calu-3) possess multiple features of in
vivo airway epithelium and have been used previously as an in vitro
model for multiple studies of influenza virus-host interaction
(19–21) or for studying other respiratory viruses (22, 23). Here,
polarized confluent monolayers of Calu-3 cells were infected api-
cally with the avian-origin IAVs A/Anhui/01/2013 (H7N9) (An-
hui01), A/Netherland/219/2003 (H7N7) (NL219), A/Vietnam/
1203/2004 (H5N1) (VN1203), or a human seasonal virus,
A/Panama/2007/1999 (H3N2) (Pan99) at a multiplicity of infec-
tion (MOI) of 1. Viral replication was assessed at 3, 7, 12, and 24 h
postinoculation [hpi] by standard plaque assays. As shown in
Fig. 1, H7N9 replicated to levels similar to those of H5N1 at 3 hpi,
and to those of other IAVs at 12 hpi. Titers of H7N9 were slightly
lower than those of other IAVs at 7 hpi but reached a slightly
higher peak at 24 hpi, with an average number of PFU/ml of 8.3
(0.04) for H7N9 and 7 (0.3) for other IAVs. Cytopathic effects
and destruction of the cell monolayer were observed at 24 hpi for
human H3N2 and avian H7N7 IAVs and to a more limited extent
after infection by H7N9 and H5N1 IAVs.
The global transcriptomic response to H7N9 is specific and is
intermediate between the cell responses to avian and human
IAVs. To assess the whole transcriptomic cellular response to IAV
infection, we used several metrics (Fig. 2). First, multidimensional
scaling (MDS) was used to visualize Euclidian distances between
each transcriptomic profile in two dimensions (Fig. 2A). In this
plot, each sample is represented by a dot; samples with similar
transcriptomic profiles (i.e., a small Euclidian distance) are close
together, while increasing distance is relative to increasing tran-
scriptomic dissimilarity. We observed that samples clustered by
time point and viral treatment, indicating a good agreement be-
tween biological replicates. At 3 and 7 hpi, IAV-infected samples
were very similar to mock-infected ones (mocks), suggesting few
transcriptomic changes early after infection, while the distance
from mocks increased at 12 and 24 hpi. At 24 hpi, each viral con-
dition was in a distinct location, indicating a specific response to
each IAV. However, while avian H5N1 and H7N7 samples were
relatively close together, H7N9 samples were located relatively far
from each of the other IAVs, indicating a specific host response to
this virus. To determine whether the host response to H7N9 in-
fection was closer to the avian or human IAV response, we mea-
sured the transcriptomic distance between Anhui01-infected and
other IAV-infected samples at each time point (Fig. 2B). At 12 hpi,
H7N9 was significantly closer to both H7N7 and H5N1 than to
H3N2. Surprisingly, at 24 hpi, the shortest distance was between
H7N9 and H3N2, while the largest distance was between H7N9
and H7N7, indicating that responses to H7N7 and H7N9 were the
FIG 1 H7N9 replicates to a level similar to that of other influenza A viruses
(IAVs) in polarized human bronchial epithelial Calu-3 cells. Polarized Calu-3
cells were infected apically with Anhui01 (H7N9), NL219 (H7N7), Pan99
(H3N2), or VN1203 (H5N1) at an MOI of 1 for an hour. After washing,
medium was added and supernatants were collected at 3, 7, 12, and 24 h for
determination of viral titers by standard plaque assay. Cells were harvested at
the same time postinfection for transcriptomic profiling. Values represent
means of titers in PFU/ml from quadruplicate wells  SD.
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most distinct. Of note, the response to H7N9 infection was as
different from that of mock samples as that to avian IAV at 24 hpi,
suggesting very specific response to H7N9 infection. Finally, to
determine transcriptomic distances between all IAV- and mock-
infected samples at each time point, we used hierarchical cluster-
ing (Fig. 2C). This analysis confirmed that H3N2 induced the
largest host response early after infection and that at 24 hpi, re-
sponses to H7N7 and H5N1 were the most similar, while the re-
sponse to H7N9 was closer to that to H3N2.
Altogether, these results show that the host response to H7N9
is highly specific to this virus but has globally more similarities
with the response to H3N2 than to those to other IAVs at 24 hpi.
Interestingly, although H7N9 and H7N7 have similar HA se-
quences, the host responses to these two viruses were very differ-
ent.
Functional characterization of host responses specific to
H7N9 and to human and avian IAVs. To further study specifici-
ties in the host response to each IAV, we identified genes differen-
tially expressed (DE) between IAV-infected samples and mock-
infected samples for each time point using the following criteria: a
q value of 0.01, as determined by Limma’s empirical Bayes mod-
erated t test, and a log2 fold change (log2FC) value of 1.5 (Fig. 3).
Consistent with transcriptomic distance analysis, IAVs induced
few transcriptomic changes at 3 and 7 hpi (Fig. 3A). At 12 hpi, the
response to H3N2 infection was quite robust, with 1,631 DE
genes, while there were only 824 DE genes after H7N9 infection
FIG 2 The host response to H7N9 infection is specific but closer to that to H3N2 than to the response to other avian-origin IAVs at late time points. (A)
Similarities in transcriptomic responses are depicted using nonparametric multidimensional scaling (MDS). Each RNA sample is represented as a single point
colored by viral treatment and with a different shape according to the time point. Euclidian distance was calculated using the whole normalized transcriptomic
data, such that proximity indicates similarity, whereas distance indicates dissimilarity, of gene expression profiles. Kruskal’s stress quantifies the quality of the
representations as a fraction of the information lost during the dimensionality reduction procedure. (B) Average distances between Anhui01-infected samples
and time-matched infected or mock samples quantifying whole-transcriptome diversity after infection. Pearson correlation distance (Pearson cor distance) is
defined as 1  Pearson correlation coefficient calculated using normalized transcriptomic data. Error bars indicate SD. Similar results were obtained with
Euclidian, Manhattan, or Spearman correlation distance (data not shown). (C) Hierarchical clustering by average linkage of IAV- and mock-infected samples at
each time hpi based on their gene expression profiles. Distances were calculated using Pearson correlation distance, but similar clustering was observed with other
distance metrics.
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and 580 and 331 for H7N7 and H5N1, respectively. At 24 hpi, all
IAVs induced a drastic host response, with the number of DE
genes ranging from 5,187 genes for H3N2 to 10,637 genes for
H5N1 and 11,413 genes for H7N7. With 6,618 DE genes for H7N9
at 24 hpi, the amplitude of the host response to H7N9 at 24 hpi was
closer to that for human than that for
avian IAV (Fig. 3A). Therefore, we ob-
served a more progressive host response
to human H3N2 infection, whereas avian
IAVs delayed the host response until
24 hpi, when a massive dysregulation of
the host response was observed. The re-
sponse to H7N9 was characterized by a
number of DE genes intermediate be-
tween those of avian and human IAVs.
In total, 16,327 genes were DE in at
least one viral treatment and at one time
point (Fig. 3B). For each gene, we defined
whether the gene was up- or downregu-
lated during the course of infection or, for
a minority of genes, had a transient ex-
pression pattern. Using this DE profile,
the 16,327 DE genes were grouped in 25
clusters and functional enrichment was
performed for each cluster (Table 1; see
also Fig. S1 to S3 in the supplemental ma-
terial).
More than 20% of the total DE genes
were specific to H7N9 infection, with
genes changing only in response to H7N9
(clusters 9, 13, and 16: 1,929 genes) or
genes dysregulated by all IAVs except
H7N9 (clusters 2 and 24: 1,565 genes).
Genes specifically induced by H7N9 were
broadly enriched among genes implicated
in global regulation of gene transcription
and the cell cycle (Table 1; see also Fig. S1
to S3 in the supplemental material). In-
terestingly, the top predicted regulator of
cluster 9 was MLL, a histone methyltrans-
ferase involved in epigenetic regulation of
diverse gene types associated with cell cy-
cle regulation and development (Table 1).
Regulation of transcription and the cell
cycle by H7N9 could be related to specific
interactions between H7N9 proteins and
nuclear factors. Among the genes signifi-
cantly upregulated by all IAVs except
H7N9 (cluster 2) were several interferon
(IFN) type 1 genes (IFN-A10, IFN-A16,
IFN-A21, and IFNw1), IL-27, IL-32, and
IL-12A (see Fig. S4A). Most other cyto-
kines were induced by all IAVs and be-
longed to cluster 1. However, closer ex-
amination of the cytokine induction level
revealed an earlier and stronger induction
after H3N2 infection than with avian
IAV, especially for CCL5, CXCL10, IFN-
B1, IL-12A, IL-1A, and IL-6 (see Fig. S4A).
Among avian IAVs, levels for some cyto-
kines, including CCL5, IFN-A7, and IFN-B1, were significantly
lower in response to H7N9 infection than to infection with H7N7
or H5N1 (see Fig. S4A).
More than 12% of the whole DE gene list was changed similarly
in response to the H7N9, H7N7, and H5N1 viruses, including
FIG 3 H7N9 induces a robust host response at 24 hpi that contains unique signatures and signatures
in common with those induced by other avian and human IAVs. (A) Numbers of upregulated (red) and
downregulated (green) differentially expressed (DE) genes after infection with IAV compared to time-
matched mocks. Criteria used for differential expression analysis are a q value of 0.01 as determined
by Limma’s empirical Bayes moderated t test and |log 2FC|  1.5. (B) Heat map depicting the expression
values of 16,327 genes DE after infection of at least one virus at one time point. For each viral condition,
DE genes were classified as up- or downregulated across infection or with a transient expression for
genes both up- and downregulated during the time course of infection. These DE profiles are shown in
blue on the right of the heat map. Genes were clustered in 25 clusters by a constant height cut of the
hierarchical clustering dendrogram of Euclidean distance of DE profiles. Functional enrichment for
each cluster is presented in Table 1 and in Fig. S1 to S3 in the supplemental material.
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regulation Top GO BP
GO





1 1,218 Up by all viruses Type I interferon-mediated
signaling pathway




2 864 Up by all but not
significantly by
H7N9




3 465 Up by all but not
significantly by
H3N2
Negative regulation of T cell
activation
3.0 cAMP-mediated signaling 1.3 EGOT 1.8
4 297 Up by H7N9 and 1 or
2 other viruses
Inflammatory response 5.6 IL-10 signaling 6.4 Poly(rI · rC)
RNA
15.1






3.1 HMGB1 signaling 2.0 Lipopolysac-
charide
5.6
6 205 Up by H3N2 and
H5N1 or H7N7
Positive regulation of nitric
oxide bio-synthetic
process
5.3 Cross talk between dendritic cells
and natural killer cells
5.8 Poly(rI · rC)
RNA
7.8





2.9 Eicosanoid signaling 2.3 POU3F3 3.6
8 287 Up by H3N2 only Gamma interferon-mediated
signaling pathway
8.2 Antigen presentation pathway 7.7 IFNG 19.9
9 686 Up by H7N9 only Regulation of transcription,
DNA dependent
6.9 Cyclins and cell cycle regulation 3.0 MLL 5.5
10 1,105 Up by H7N7 only Genes 4.3 Nucleotide excision repair
pathway
2.3 INPP1 2.9
11 474 Up by H5N1 only Arginine metabolic process 2.6 NFKB activation by virus 1.6 FRS2 4.4




4.2 Granulocyte adhesion and
diapedesis
3.1 IL1 4.7
13 241 Up by H7N9 but down







14 52 Down by H7N9 but up
by one other virus
Antigen processing and
presentation of peptide or
polysaccharide antigen via
MHC class II
10.9 Antigen presentation pathway 9.3 CIITA 4.8
15 1,091 Down only by H7N7 Regulation of transcription,
DNA dependent
12.0 Role of NFAT in cardiac
hypertrophy
3.6 Beta-estradiol 4.6
16 1,002 Down only by H7N9 Proteolysis 9.6 Serotonin degradation 5.6 MYC 7.6
17 676 Down only by H5N1 tRNA processing 3.7 Role of BRCA1 in DNA damage
response
3.0 I kappa B
kinase
3.1





2.8 TR/RXR activation 2.8 TRIM63 3.5




3.6 Role of BRCA1 in DNA damage
response
3.7 CDH1 2.9








21 217 Down by H7N7 and
H3N2
Sodium ion transport 2.9 Triacylglycerol biosynthesis 2.3 Cisplatin 2.5
22 617 Down by at least 2
viruses
Ethanol oxidation 4.3 Ethanol degradation IV 5.0 Meloxicam 5.7
23 871 Down by all but H3N2 Transmembrane transport 8.2 GDP-mannose biosynthesis 2.6 mir-210 4.1
24 701 Down by all but H7N9 Regulation of transcription,
DNA dependent
12.8 Factors promoting cardiogenesis
in vertebrates
3.7 ASXL1 2.8
25 813 Down by all viruses Xenobiotic metabolic
process
5.2 Alpha-tocopherol degradation 3.5 HNF1A 6.3
a Most-enriched gene ontology (GO) biological process (BP), IPA canonical pathway (path.), and top regulator (reg.) were reported for each cluster identified in Fig. 3. Enrichment
scores (ES) were calculated as –log10 P values, using a right-tailed Fisher exact test.
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genes up- and downregulated similarly by each of these viruses
(clusters 3 and 23: 1,336 genes) and genes similarly unchanged
after avian IAV infection and dysregulated only after H3N2 infec-
tion (clusters 8 and 18: 667 genes). Cluster 8 was particularly in-
teresting, since it included several genes from the antigen presen-
tation pathway upregulated only after H3N2 infection, including
those encoding class I major histocompatibility complex (MHC)
molecules (HLA-A, HLA-B, and HLA-F) and transcription factors
(CIITA and NLRC5). Some genes belonging to the antigen presen-
tation pathway were also found in cluster 14 and were downregu-
lated after H7N9 infection but upregulated in H3N2-infected
cells, and these included genes encoding class II MHC molecules
(HLA-DPA1, HLA-DPB1, HLA-DRA, HLA-DRB1, HLA-DRB4,
HLA-DRB5, and CD74) (see Fig. S4B in the supplemental mate-
rial).
Finally, more than 20% of the DE genes had similar profiles in
H7N9 and H3N2 IAV versus H5N1 and H7N7 IAVs: these genes
were significantly DE only after H5N1 and H7N7 infection (clus-
ters 7 and 20: 3,388 genes). These genes could reflect adaptation of
H7N9 to the human host, similar to findings for the seasonal
H3N2 virus. Cluster 7 genes were significantly upregulated only in
H5N1- and H7N7-infected samples and included genes from the
eicosanoid signaling pathway (see Fig. S4C in the supplemental
material). Upstream of this pathway, gene expression levels for
PLA2G5 were 2 to 4 times more increased after H7N7 and H5N1
infection than after that with H3N2 and H7N9 at 24 hpi; PLA2G5
encodes a phospholipase A2 enzyme that catalyzes arachidonic
acid production, a key inflammatory intermediate that is further
catalyzed in different lipid mediators, regulating many biological
processes, including inflammation and immune function. Several
receptors of eicosanoids (LTB4R, TBXA2R, and PTGER3) were
also more increased by H5N1 and H7N7 than by H7N9 or H3N2
IAVs. Forty-seven genes from cluster 20 were involved in chroma-
tin modification, with the majority of genes involved in this bio-
logical process having similar profiles between H7N9 and H3N2
versus H5N1 and H7N7, but some genes were specifically upregu-
lated only in H7N9-infected samples (cluster 9 and 13 genes) (see
Fig. S5). This could reflect both H7N9-specific and human-IAV-
like ability to modify expression of genes involved in chromatin
and epigenetic regulation.
In conclusion, cluster analysis revealed an extensive list of
functions dysregulated specifically by H7N9 or similar to findings
for other IAVs, including proinflammatory cytokines, the antigen
presentation pathway, and several nuclear pathways. Confirming
transcriptomic distance analysis, there were more similarities be-
tween H5N1 and H7N9 responses, with 2 clusters specific to these
viruses (clusters 5 and 19), than between H7N7 and H7N9, since
there was no gene DE specifically in response to H7N9 and H7N7
only.
Transcriptome-based antiviral prediction. We have previ-
ously shown that drugs reversing the host response to IAV or
coronavirus infection may inhibit viral replication (24, 25). In an
effort to identify such potential antivirals that target the cellular
response to these IAVs, we used two independent and comple-
mentary methods. The first method is a literature-based predic-
tion using the Ingenuity Knowledge Database that identifies mol-
ecules known to regulate DE genes in an opposite direction
(z score  2) from that with IAV infection (Fig. 4A). For each
IAV, potential antivirals were identified as upstream regulators
having significant z scores on at least 2 time points and no positive
z scores at any other time point. Only a few drugs were identified
as potential anti-H7N7 therapies while 23 compounds were iden-
tified as potential regulators of the response to H3N2 IAV. Thir-
teen compounds were identified as negative regulators of the re-
sponse to H7N9, including several kinases inhibitors (SB203580,
U0126, SP600125, LY294002, genistein, SB202190, JAK inhibitor
I and KN-32), immunosuppressive drugs (cyclosporine A, fon-
tolizumab, infliximab, etanercept) and one antibiotic (minocy-
cline). Other drugs that were predicted antivirals for H5N1 and
H3N2, but with lower z score for H7N9, included chloroquine,
aspirin and resveratrol.
To confirm these predictions, we used a second independent
method which is a data-driven prediction based on the Connec-
tivity Map (Cmap). Cmap is a database of more than 7,000 gene
expression profiles, representing 1,309 compounds, and we used it
to identify drugs reverting IAV signatures (Cmap score close to
1) or inducing changes similar to those induced by IAVs (Cmap
score close to 1) (Fig. 4B). Because Cmap profiles were generated
using cell lines and array platforms different from those in this
experiment, we used these results as a second line of validation,
considering only drugs predicted in the Ingenuity Pathways
Knowledge Base (IPA). Among the 26 compounds predicted to be
upstream regulators of at least 1 IAV, 10 were found to be signif-
icant in Cmap. Relationships between these 10 drugs and each
viral condition are depicted as a drug-virus network (Fig. 4B).
These results confirmed that SB-203580 and genistein reverted the
host response to all 4 IAVs. Conversely, SB-202190 and resveratrol
were found to induce gene expression changes similar to those
induced by IAV. Troglitazone and LY-294002 were predicted to
reverse H7N9 signatures across infection but had positive Cmap
scores for some viral treatment: H5N1 at 24 hpi for troglitazone
and H3N2 and H7N7 at 7 hpi for LY-294002. Finally, some drugs
had strain-specific effects, such as minocycline, predicted in both
IPA and Cmap to negatively regulate H7N9 signatures, or simva-
statin, which induced effects opposite to those of H3N2 only.
Altogether, a combination of two different approaches identi-
fied the kinase inhibitor SB-203580 and genistein as capable of
reversing the host response to all tested IAVs, including H7N9.
Additional molecules identified by both methods as reverting
H7N9 signatures were troglitazone, minocycline, and LY-294002.
In vitro evaluation of minocycline antiviral activity. To vali-
date our drug prediction, we evaluated the ability of minocycline,
a tetracycline, to inhibit H7N9 viral replication in vitro. This mol-
ecule was chosen because it was predicted to reverse H7N9 signa-
tures by both computational methods but had not been tested
previously against influenza virus. Using a colorimetric viability
assay, the 50% cytotoxicity concentration of minocycline on
Calu-3 cells was evaluated to be around 1,000 M, and we ob-
served no significant cytotoxicity up to 266 M (see Fig. S6 in the
supplemental material). To evaluate potential antiviral effect of
minocycline, polarized Calu-3 cells were pretreated with increas-
ing concentrations of minocycline for 3 h and infected with An-
hui01 at an MOI of 0.01 (Fig. 5). At 24 hpi, there was a significant
decrease of 1.3 log10 (17%) of Anhui01 viral titers in cells treated
with 200 M minocycline (P  0.01). Lower concentrations of
minocycline did not inhibit Anhui01 viral replication. Ribavirin,
an antiviral drug with in vitro activity against both DNA and RNA
viruses, was used as a positive control and induced a more robust
decrease of 5.3 log10 (71%) of the log10 viral titer (Fig. 5). Overall,
these data show that minocycline exerts a modest but significant
Josset et al.
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FIG 4 Potential antiviral prediction based on transcriptomic profiles after IAV infection. (A) Prediction based on expression of known targets for molecules
within the IPA database. A negative z score indicates that the regulator is known to downregulate the same genes that were significantly upregulated after infection
and/or to upregulate genes that were downregulated after infection. Dashed lines depict the limit of significance (|z score|  2). For each virus, z scores were
calculated using log2FC expression of DE genes at each time point, and molecules with significant negative z scores for at least 2 time points were selected for this
representation (29 drugs). Potential antivirals were defined as drugs with a z score  2 for at least 2 time points and no positive z score (molecules highlighted
in color). Twenty-six regulators were predicted to have an effect opposite to that of infection for at least one IAV. Molecules were ranked from most- to
least-negative mean z score across all conditions. (B) The Connectivity Map (Cmap) was used to confirm potential anti-IAV effects of regulators predicted in IPA.
Gene expression profiles for 10 molecules (out of the 26) were found in the Cmap database and compared with IAV-infected profiles. Cmap scores go from 1
to 1, with positive scores for drugs inducing changes similar to the viral signature and negative scores for opposite changes. Relationships between viral signatures
and drugs were depicted in a network with a circular layout. Edges between virus and drugs are colored based on the Cmap scores comparing drug and viral
profiles at each time point. Drugs are colored based on the mean of the Cmap scores for all time points. Drugs colored in orange induced gene expression changes
that are the reverse of those for IAVs after cell treatment. Note that the Cmap query requires a list of up- and downregulated genes and was therefore not
performed for VN1203 at 7 and 12 hpi, for which there were too few downregulated genes.
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antiviral effect against H7N9, validating our in silico drug screen-
ing.
DISCUSSION
Although the H7N9 outbreak has entered a stationary state in
China, with only a few cases reported since late May 2013, there
are concerns that H7N9 may reappear in the winter. Other avian
IAVs, such as H5N1, indeed have a seasonal pattern, with an in-
crease in human infection during the winter. In addition, H7N9 is
likely still circulating in poultry. Several studies have shown that
H7N9 possess genetic markers associated with adaptation to hu-
mans, allowing higher replication in mammal cells (PB2 E627K)
and increased binding of 2-6 human receptors (HA Q226L and
G186V). Further adaptation of H7N9 to humans is of concern,
since it could lead to efficient human-to-human transmission. In
this study, we have shown that cell responses to H7N9 infection
are more similar to those to H3N2 infection than to those to in-
fection with avian H5N1 or H7N7 viruses, which implies that
H7N9 has adapted to the human host. Some of the human IAV-
like transcriptomic responses of H7N9 were related to similar
lower induction of several genes involved in the eicosanoid path-
way. Some lipid mediators from these pathways were recently
identified as correlates of the pathogenic or resolution phase of
IAV infection in mice (26) and had antiviral effect in cells and
mice (27). Our analysis revealed that the eicosanoid pathway is
differentially regulated by avian and human IAVs, with a potential
impact on lung inflammation and viral replication.
Importantly, differences in the transcriptomic response to in-
fection were not related to major differences in replication be-
tween viruses. We previously observed higher replication of the
Anhui01 H7N9 strain than of the seasonal A/Texas/50/2012
(H3N2) virus in Calu-3 cells (14). However, at this higher MOI
and using the more replicative A/Panama/2004/99 (H3N2), sim-
ilar replication between avian and human IAVs was observed.
Surprisingly, the most distinct response was between H7N9
and H7N7, despite genetic similarities between HA segments.
Therefore, analysis of viral sequences alone cannot predict the
host response to infection. Analysis between HA and human re-
ceptors has revealed that H7N9 has a profile intermediate between
those of human and avian IAVs. Here, we observed that the host
response to H7N9 shared some similarities with the response to
human and avian IAVs, but we also observed a large amount of
specificity in the cell response to H7N9 infection. Genes signifi-
cantly induced by H7N9 were involved in cell cycle regulation,
transcription, and epigenetic modifications. Consistent with find-
ings of a previous study in polarized Calu-3 cells (19), we noted
that avian IAVs induced a weaker proinflammatory cytokine re-
sponse than human IAV. For genes coding for type I IFN and some
other cytokines, this reduced cytokine induction was even more
striking in H7N9-infected than in H5N1- or H7N7-infected sam-
ples. The ability to delay the antiviral host response could also have
a major impact on in vivo pathogenesis of H7N9 human infection.
Finally, genes coding for antigen presentation pathway proteins
were upregulated only in H3N2-infected cells, while the expres-
sion of these genes was either unchanged by avian IAVs or down-
regulated by H7N9 virus. Notably, downregulation of the antigen
presentation pathway was also observed in nonpolarized Calu-3
cells infected with avian VN1203 H5N1 virus while upregulated
following human A/California/04/2009 (H1N1) infection or al-
pha IFN (IFN-) treatment (V. D. Menachery, A. J. Eisfeld, L.
Josset, A. C. Sims, M. G. Katze, Y. Kawaoka, and R. S. Baric, un-
published data). Therefore, downregulation or absence of induc-
tion of antigen presentation in infected epithelial cells is a charac-
teristic of avian versus human IAVs. Given concerns about the
immunogenicity of avian H5N1 and H7N9 viruses, mechanisms
of antigen presentation pathway control and its implication in
vivo warrant further exploration.
Because no vaccine for the prevention of H7N9 infections is
currently available, prophylaxis and treatment rely on antivirals.
Studies in mice (28) and in a patient (29) have shown low efficacy
of NA inhibitors for H7N9 morbidity. Moreover, emergence of
H7N9 virus resistant to NA inhibitors has been observed (18), and
one of the resistance mutations (NA-R292K) induced high-level
oseltamivir resistance without impairing viral replication and in
vivo virulence (30). Finally, ribavirin, which shows in vitro activity
against influenza viruses, including H7N9, is not currently ap-
proved for the treatment of influenza and has controversial effi-
cacy in vivo (31). Developing alternative antiviral therapeutics is
therefore a priority. Genome-based drug repurposing strategies
relying on the identification of drugs reversing cell responses to
viral infection have successfully identified antivirals against IAVs
(25) and coronavirus (24). These strategies have the advantage of
being able to screen a large number of available drugs in silico and
potentially accelerate their use in clinics. Here, we used a combi-
nation of two complementary methods, a knowledge-based ap-
proach (using IPA) prioritizing drugs with published effects that
are opposite to IAV-induced gene expression changes, and a data-
based approach using drug gene expression profiles present in
Cmap to determine whether drug treatment induced transcrip-
FIG 5 Antiviral activity of minocycline. Polarized Calu-3 cells were treated
with increasing concentrations of minocycline for 3 h and infected with An-
hui01 at an MOI of 0.01. Viral titers were determined at 24 hpi. Ribavirin at
50 M was used as a reference. Values represent means of titers in PFU/mL
from triplicate wells  SD. *, P  0.01 (Student’s t test).
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tomic changes opposite to viral infection. Twenty-six molecules
were predicted by the first method to modulate the host response
to at least one IAV, and out of the 10 present in Cmap, 8 were
found to induce gene expression changes opposite to IAV signa-
tures after multiple cell line treatment. Drugs that were predicted
by both methods for H7N9 were the kinase inhibitors SB203580,
genistein, LY-294002, and the antibiotic minocycline. In addition,
the antidiabetic drug troglitazone, which was just below our
threshold for IPA prediction, was found in Cmap to significantly
revert H7N9 signatures at 3, 7, and 12 hpi.
Importantly, we evaluated the anti-H7N9 activity of minocy-
cline, a tetracycline with antimicrobial action, and independent
anti-inflammatory and neuroprotective properties. We observed
that minocycline significantly inhibited H7N9 replication in vitro.
Minocycline was previously shown to inhibit simian immunode-
ficiency virus and human immunodeficiency virus (SIV and HIV)
replication in vitro and in vivo and to reduce SIV-induced enceph-
alitis severity in macaques (32). Minocycline was also shown to
inhibit West Nile virus replication in vitro, possibly by inhibiting
Jun N-terminal protein kinase (JNK) induction (33), and to pro-
tect mice against Japanese encephalitis virus infection (34). This
study is the first, to our knowledge, to show that minocycline also
inhibits influenza virus replication in vitro. Moreover, this assay
validates our in silico drug prediction. Minocycline is an interest-
ing candidate to consider for in vivo testing, since it is FDA ap-
proved, readily available, and well tolerated. In addition to mino-
cycline’s antiviral activity, its neuroprotective effect may
potentially prevent influenza-associated neurological complica-
tions.
Our in silico drug prediction was further validated by literature
mining, revealing that out of the 26 drugs predicted to have an
effect on at least one IAV in the present study, 17 have already been
tested against influenza in cell or mouse models and 14 had anti-
viral effects in those tests (see Table S1 in the supplemental mate-
rial). Among the 3 drugs that did not show any effect on influenza
virus replication or pathogenicity, dexamethasone was predicted
only to be a potential anti-H7N7 agent, since it had a positive
z score for H7N9, H3N2, and H5N1 infections at early time points
and could therefore increase early viral replication. This could be
linked to the controversial role of corticosteroids in patients with
influenza acute respiratory distress syndrome (ARDS), for which
very early corticosteroid therapy may be harmful (35). Most likely,
several drugs predicted here that had previously known anti-IAV
effects may have broad antiviral effects and could be active against
H7N9. FDA-approved drugs that are already used in clinics for
diverse indications but not influenza and that were identified in
our in silico screening and with previously published anti-
influenza effects, such as chloroquine (36), are particularly inter-
esting to consider for therapeutic intervention against H7N9.
The in vivo pulmonary host response and outcome for influ-
enza infection cannot be determined by directly transposing tran-
scriptomic profiles from single cell types. The whole-lung re-
sponse to infection depends on the interaction between infected
cells, immune cells, and the lung microenvironment. In addition,
the host response to influenza infection depends on the cell type
and differentiation levels of infected cells (37). We have high-
lighted in a recent review that novel mathematical models are
needed to model interactions between cells and to integrate in
vitro and in vivo studies (38). By using a multivariate modeling
approach, McDermott et al. were able to predict pulmonary ex-
pression of conserved regulatory modules in macaques and mice
in response to H5N1 infection from a regulatory model built from
Calu-3 cells infected with H5N1 (39). In addition, numerous
studies have shown that cell cultures are extremely useful experi-
mental models for extended influenza virus-host interaction stud-
ies and for the screening of potential antivirals. In particular, po-
larized Calu-3 cells were shown to be valuable models for the study
of influenza virus and supported viral replication and type I IFN
responses similarly to primary human bronchial epithelial (HBE)
cells (19). Culture systems of differentiated primary epithelial cells
from humans, like HBE cells, recapitulate more closely the mor-
phological features of the human upper airway but provide a less
convenient and reproducible model for the study of influenza
virus because of experiment, passage, and donor variations, in-
ducing a variable differentiated phenotype (40). In this study, we
used Calu-3 cell cultures to rapidly characterize the emerging
H7N9 virus by comparing its response to several avian and human
influenza viruses and to perform in silico screening for potential
antivirals. We believe that this data set is a valuable resource for
further studies of H7N9 and other influenza viruses. In two ongo-
ing studies, we have been profiling mouse and macaque pulmo-
nary responses to H7N9 infection (J. Morrison, L. Josset, N.
Tchitchek, J. Chang, J. Belser, T. Tumpey, and M. G. Katze, sub-
mitted for publication; E. de Wit, A. Rasmussen, F. Feldmann, T.
Bushmaker, C. Martellaro, E. Haddock, A. Okumura, S. Proll, J.
Chang, D. Gardner, M. G. Katze, and V. J. Munster, submitted for
publication). Importantly, we found that a significant number of
drugs predicted to reverse Calu-3 cell responses to H7N9, includ-
ing minocycline, SB203580, KN-62, and Jak Inhibitor 1, were also
predicted to reverse the mouse and macaque pulmonary response
to H7N9 infection (Morrison et al., submitted). This demon-
strates conserved functional responses between these models.
In conclusion, high-throughput profiling of the cellular re-
sponse to H7N9 infection and comparison to those to other avian
IAVs or a seasonal human H3N2 virus revealed that H7N9 in-
duced both specific responses and responses in common with
avian or human IAVs. Transcriptomic profiles similar to those of
H7N9 and H3N2 indicate potential human adaptation of H7N9,
and further evolution toward the response to human IAVs could
be surveyed with novel H7N9 isolates. Our analysis pointed out
several FDA-approved drugs, including minocycline, as potential
anti-H7N9 drugs that would be important to explore in vivo.
MATERIALS AND METHODS
Viruses. Three avian-origin IAVs isolated from fatal human cases, A/An-
hui/01/2013 (H7N9) (Anhui01), A/Netherland/219/2003 (H7N7)
(NL219), and A/Vietnam/1203/2004 (H5N1) (VN1203), and a seasonal
human virus, A/Panama/2007/1999 (H3N2) (Pan99), were used in this
study. Virus stocks were grown in the allantoic cavities of 10-day-old
embryonated hen’s eggs for 24 to 28 h at 37°C for avian-origin IAVs or for
48 h at 34°C for the H3N2 virus. Allantoic fluids from multiple eggs were
pooled, clarified by centrifugation, aliquoted, and stored at 70°C. Virus
titers were determined by a plaque assay as previously described (19). All
research with avian viruses was conducted under biosafety level 3 contain-
ment, including enhancements required by the U.S. Department of Agri-
culture and the Select Agent Program (http://www.cdc.gov/od/ohs
/biosfty/bmbl5/bmbl5toc.htm).
Cell culture and viral infection. The human bronchial epithelial cell
line Calu-3 was originally derived from subbronchial epithelium of a lung
adenocarcinoma (ATCC), and cells were grown as previously described
(19). Confluent monolayers of polarized Calu-3 cells achieving stable
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transepithelial resistance were infected apically at an MOI of 1. After a 1-h
incubation, monolayers were washed to remove nonadherent virus and
2 ml of minimal essential medium-bovine serum albumin (MEM-BSA)
was added to both apical and basolateral reservoirs of cells and left for the
duration of the experiment.
RNA isolation and microarray processing. RNA extraction from
IAV- and mock-infected Calu-3 cells in quadruplicate was performed as
previously described (41). Probe labeling and microarray slide hybridiza-
tion for each biological replicate were performed using a SurePrint G3
Human Gene Expression 860K v2 microarray (Agilent Technologies)
according to the manufacturer’s instructions. Slides were scanned on an
Agilent DNA microarray scanner (model G2505B) using the XDR setting,
and raw images were analyzed using the Agilent Feature Extraction soft-
ware program (version 9.5.3.1). Extracted raw data were background cor-
rected using the norm-exp method with an offset of 1 and quantile nor-
malized using the limma software package (42) in the R environment.
Replicated probes were mean summarized. All probes were required to
pass Agilent quality control (QC) flags (“gIsFound,” “gIsWellAboveBG,”
“gIsSaturated,” “gIsFeatNonUnifOL,” and “gIsFeatPopnOL”) for all rep-
licates of at least one infected time point (29,382 probes passed QC filter-
ing). For each sample, a log2FC value was calculated as the difference
between log2-normalized data for this sample and the average of log2-
normalized data for time-matched mocks. Microarray annotation was
retrieved from the GEO data bank (GEO accession no. GPL17077).
Statistical analysis. Differential expression was determined by com-
paring IAV-infected replicates to time-matched mocks, based on a linear
model fit for each probe using the R software package “limma” (42).
Criteria for differential expression were an absolute log 2FC of 1.5 and a q
value of 0.01 calculated using a moderated t test with subsequent
Benjamini-Hochberg correction. This controls the false discovery rate
(FDR) associated with our results to 1%. For each viral condition, genes
were classified as up- or downregulated throughout infection if they were
found significantly up- or downregulated at at least one time point. Genes
that were found to be both up- and downregulated at different time points
were classified as genes with transient expression. A binary DE matrix with
3 columns per viral treatment (gene up- or downregulated or transient
genes) and values equal to 1 for DE and 0 for not DE was used to cluster DE
genes in 25 clusters by Euclidian distance and constant height cut of a
hierarchical clustering dendrogram (43).
Transcriptomic distance analysis. To visualize transcriptional simi-
larity between samples in a 2-dimensional space, Euclidian distances were
calculated with transcriptomic normalized data, and nonmetric multidi-
mensional scaling (MDS) was performed using the MASS software pack-
age in the R Bioconductor program (44) to map the distances into the
2-dimensional space with minimal loss of information (evaluated by
Kruskal’s stress). Biological replicates from the same condition were
linked in convex hulls (i.e., polygons) using the function “chull” in R.
Pearson correlation coefficients, Spearman correlation coefficients, total
Euclidean distances, or total Manhattan distances were used to estimate
similarities in the gene expression profiles between Anhui01-infected and
other IAV- or mock-infected samples. The average distance between con-
ditions was calculated as the arithmetic mean of distances between all
biological replicates.
Functional enrichment and upstream regulator analysis. Functional
analysis of statistically significant gene expression changes was performed
using the Ingenuity Pathways Knowledge Base (IPA; Ingenuity Systems).
For all gene set enrichment analyses, a right-tailed Fisher exact test was
used to calculate a P value determining the probability that each biological
function assigned to that data set was due to chance alone. All enrichment
scores were calculated in IPA using the probes that passed our QC filter as
the background data set.
Upstream regulator analysis, which was used to predict regulators and
infer their activation state, is based on prior knowledge of expected effects
between regulators and their known target genes according to the IPA
database. A z score is calculated and determines whether gene expression
changes for known targets of each regulator are consistent with what is
expected from the literature (z score  2) or if the changes are anticorre-
lated with the literature (z score  2). To predict potential antivirals, we
queried the IPA database with the list of DE genes at each time point for
each IAV, and we selected the molecules annotated “chemical drug,” “bi-
ologic drug,” “chemical— kinase inhibitor,” or “chemical—protease in-
hibitor” having a z score of 2 on at least 2 time points and no positive
z score at other time points.
Connectivity map. To confirm whether drugs identified in IPA induce
signatures opposite to those induced by IAVs, we used the publicly avail-
able Connectivity Map (Cmap) database (build 02) (45). The Cmap is a
collection of genome-wide transcriptional data from cultured human
cells treated with 1,309 different compounds. We used the lists of DE
genes up- and downregulated at each time point under each viral condi-
tion, limiting to the top 250 most up- and downregulated genes for lists
containing a higher number of genes. Agilent probes were mapped to
Affymetrix U133A probe sets using the BioMart ID converter tool (46) in
order to query the Cmap database. Ten drugs out of the 26 potential
antivirals identified in IPA were found in the Cmap database. We analyzed
permuted results for drugs having consistent mean Cmap scores and en-
richment scores (i.e., both scores were positive or both were negative).
Relationships between drugs and viral signatures were depicted in a net-
work using Cytoscape software and a circular layout (47).
Antiviral in vitro assay. Minocycline hydrochloride (Sigma) and riba-
virin (Sigma) were dissolved in dimethyl sulfoxide (DMSO). To assay
minocycline cytotoxicity, Calu-3 cells were grown in 96-well plates treated
with increasing concentrations of minocycline for 24 h before incubation
with the WST-1 reagent (Roche) at 37°C for 1 h. A microplate spectro-
photometer was used to measure the absorbance of the samples at 450 nm
with 600 nm as the reference wavelength. For the antiviral assay, 1-week-
old polarized Calu-3 cells were treated with drugs for 3 h and infected with
Anhui01 at an MOI of 0.01 for 1 h. The inoculant was washed away, and
cells were incubated with drugs for the duration of the experiment. At
24 hpi, the apical supernatants from infected Calu-3 cells were collected
and titers were determined. Experiments were performed in triplicate.
Microarray data accession number. Raw microarray data have been
deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO series accession number GSE49840. In addition, normal-
ized matrixes and expression values utilized in this study can be found at
https://viromics.washington.edu.
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